Meeting
2020 ASCO Virtual Scientific Program
Durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Updated survival and early translational results from Big Ten Cancer Research Consortium Study.
Authors
Hirva Mamdani
Barbara Ann Karmanos Cancer Institute, Detroit, MI
Hirva Mamdani , Bryan J. Schneider , Pashtoon Murtaza Kasi , Laith I. Abushahin , Thomas J. Birdas , Kenneth Kesler , Heather Burney , Susan Perkins , Shadia Ibrahim Jalal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02639065
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4572)
DOI
10.1200/JCO.2020.38.15_suppl.4572
Abstract #
4572
Poster Bd #
180
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Results from big ten cancer research consortium study.
First Author: Hirva Mamdani
Poster
2019 Gastrointestinal Cancers Symposium
Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani
Poster
2018 Gastrointestinal Cancers Symposium
A phase II study of durvalumab following multimodality therapy for locally advanced esophageal adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-ESO14-012 study.
First Author: Hirva Mansurali Mamdani
Poster
2016 Gastrointestinal Cancers Symposium
Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
First Author: Charles S. Fuchs